Rani Therapeutics Holdings Stock Analysis

Rani Stock Analysis Notes

About 31.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.68. Rani Therapeutics recorded a loss per share of 1.04. The entity had not issued any dividends in recent years. Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company was incorporated in 2012 and is headquartered in San Jose, California. Rani Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 114 people. To find out more about Rani Therapeutics Holdings contact Talat Imran at 408 457 3700 or learn more at https://www.ranitherapeutics.com.

Rani Therapeutics Investment Alerts

Rani Therapeutics Upcoming and Recent Events

Rani Largest EPS Surprises

View All Earnings Estimates

Rani Stock Institutional Investors

Note, although Rani Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Rani Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 77.29 M.

Rani Profitablity

Management Efficiency

Rani Therapeutics has return on total asset (ROA) of (0.5683) % which means that it has lost $0.5683 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2535) %, meaning that it created substantial loss on money invested by shareholders. Rani Therapeutics' management efficiency ratios could be used to measure how well Rani Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.55. The current Return On Capital Employed is estimated to decrease to -1.6. As of now, Rani Therapeutics' Fixed Asset Turnover is increasing as compared to previous years. The Rani Therapeutics' current Asset Turnover is estimated to increase to 0.03, while Non Current Assets Total are projected to decrease to under 6.5 M.

Technical Drivers

As of the 18th of January 2025, Rani Therapeutics holds the Variance of 40.38, risk adjusted performance of (0.14), and Coefficient Of Variation of (568.95). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rani Therapeutics, as well as the relationship between them.

Rani Therapeutics Price Movement Analysis

Rani Therapeutics Insider Trading Activities

Rani Therapeutics Outstanding Bonds

Rani Therapeutics Predictive Daily Indicators

Rani Therapeutics Forecast Models

Rani Therapeutics' time-series forecasting models are one of many Rani Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rani Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Rani Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rani shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rani Therapeutics. By using and applying Rani Stock analysis, traders can create a robust methodology for identifying Rani entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rani analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rani analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Rani Therapeutics Holdings stock analysis indicators help investors evaluate how Rani Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rani Therapeutics shares will generate the highest return on investment. By understating and applying Rani Therapeutics stock analysis, traders can identify Rani Therapeutics position entry and exit signals to maximize returns.

When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.